About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 61777 record(s)
Req # A-2021-001093
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-112628-914.Organization: Health Canada
May 2022
Req # A-2021-001125
Adverse Drug Reactions (ADRs) for INSULIN GLARGINE. Report numbers: E2B_03895786, E2B_03581341, E2B_03868449, E2B_04040159, E2B_03889625, E2B_03572467.Organization: Health Canada
May 2022
Req # A-2021-001129
Adverse Drug Reactions (ADRs) for METRONIDAZOLE. Report numbers: 938434, E2B_03598788, E2B_03551852, E2B_03855683, 942803, 948620, 927672, E2B_03978866, E2B_03581497, E2B_03949972, 937385, E2B_03651427, E2B_03679537, E2B_03551750.Organization: Health Canada
May 2022
Req # A-2021-001193
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-115231-297.Organization: Health Canada
May 2022
Req # A-2021-001351
Adverse Drug Reactions (ADRs) for METFORMIN HYDROCHLORIDE. Report numbers: E2B_03943573, E2B_03836545, 000949680, 000927868, 000931808, E2B_03530023, E2B_03844386, E2B_03608095, E2B_04095388, E2B_03536707, E2B_03647498, E2B_03534311, E2B_03545193, 000939930, E2B_03524688, 000942148, 000934520.Organization: Health Canada
May 2022
Req # A-2021-001389
Adverse Drug Reactions (ADRs). Report numbers: 000609698, E2B_03523626, E2B_01076680, E2B_03525118, E2B_03551087, E2B_03551176, E2B_03552099, E2B_03559571, E2B_03570042, E2B_03571633, E2B_03592534, E2B_03594125, E2B_03594193, E2B_03595504, 000934573.Organization: Health Canada
May 2022
Req # A-2021-001431
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03682363, E2B_03710805, E2B_03710809, E2B_03733275, E2B_03739980, E2B_03673777.Organization: Health Canada
May 2022
Req # A-2021-001469
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_03960818, 937695, E2B_04064296, E2B_03908235, E2B_03765818, E2B_04075066, 936770, E2B_01971466, E2B_01935369, E2B_02396650, E2B_01971051, E2B_01982466, E2B_03542823, E2B_03595510.Organization: Health Canada
May 2022
Req # A-2021-001495
Adverse Drug Reactions (ADRs). Report numbers: E2B_04053034, E2B_03622039, E2B_03622622, E2B_03639641, E2B_03640889, E2B_03740761.Organization: Health Canada
May 2022
Req # A-2021-001508
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: 000953205, 000950478, 000937845, E2B_03835650, 000954875, 000955563, E2B_03971668, E2B_03955849, E2B_03965172, E2B_03578880, E2B_03618327, E2B_03762257, E2B_03785935.Organization: Health Canada
May 2022